EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

Nicolas Peruzzo, Gabriel Lenz, Ted Akhiwu, Mariah Bilalaga, Greeshma Nihitha Gaddipati, Nathalia Luisy Farias Müller, Loren Zarpellon, Fernando Venero, Marcelo Corassa, Andrés F Cardona, Joshua E Reuss, Bruna Pellini

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.04.006 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Nicolas Peruzzo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD; Georgetown University, Washington, DC. Electronic address: Nicolas.DaCostaPer…. Hauptthemen laut MEDLINE: Lung Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Squamous cell lung carcinoma (sqNSCLC) accounts for 25% to 30% of all non-small cell lung cancer (NSCLC) cases and is associated with a worse prognosis. Although immune checkpoint inhibitors improve outcomes in advanced sqNSCLC, the true benefit of chemotherapy plus anti-PD-(L)1 in patients with advanced PD-L1-negative sqNSCLC is unclear. MATERIAL AND METHODS: We performed a systematic review and meta-analysis of randomized clinical trials comparing chemotherapy plus anti-PD-(L)1 to chemotherapy with or without placebo in locally advanced (ineligible for concurrent chemoradiation or surgery) or metastatic PD-L1-negative sqNSCLC. RESULTS: A total of 1548 patients with advanced PD-L1-negative sqNSCLC from 11 studies were included. Of these, 810 patients (52%) received chemotherapy plus anti-PD-(L)1 (intervention group), while 738 patients (48%) received chemotherapy with or without placebo (control group). All included studies were phase 3 trials and used platinum-doublet chemotherapy regimens. Chemotherapy plus anti-PD-(L)1 was associated with increased probability of overall response rate (risk ratio, 1.36; 95% CI, 1.16-1.60; P = .0001), increased progression-free survival (HR = 0.58; 95% CI, 0.48-0.69; P < .00001), and increased overall survival (HR = 0.81; 95% CI, 0.69-0.96; P = .02) compared to chemotherapy, with or without placebo. CONCLUSIONS: Our findings support the use of combination anti-PD-(L)1 plus chemotherapy as first-line therapy for patients with advanced PD-L1-negative sqNSCLC. Prospective studies are warranted to determine whether dual checkpoint inhibition, with or without chemotherapy, is superior to anti-PD-(L)1 plus chemotherapy in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsB7-H1 AntigenImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellProgrammed Cell Death 1 ReceptorCarcinoma, Non-Small-Cell LungHumansRandomized Controlled Trials as TopicPrognosis

Stichwörter der Autor:innen

ChemotherapyImmune checkpoint inhibitorImmunotherapyLung cancerNon-small cell lung cancerPD-1 inhibitorPD-L1 inhibitorSquamous cell lung carcinoma

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD; Georgetown University, Washington, DC. Electronic address: Nicolas.DaCostaPeruzzo@gunet.georgetown.edu.
  • Department of Medicine, Hospital Regional Terezinha Gaio Basso, São Miguel Do Oeste, SC, Brazil.
  • Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD; Georgetown University, Washington, DC.
  • School of Medicine, Universidade do Sul de Santa Catarina (Unisul), Palhoça, SC, Brazil.
  • Complexo Hospitalar de Niterói, Niterói, RJ, Brazil.
  • Department of Oncology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.

Zitieren

APA

Peruzzo, N., Lenz, G., Akhiwu, T., Bilalaga, M., Gaddipati, G. N., Müller, N. L. F., Zarpellon, L., Venero, F., Corassa, M., Cardona, A. F., Reuss, J. E., & Pellini, B. (2025). Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.04.006

Vancouver

Peruzzo N, Lenz G, Akhiwu T, Bilalaga M, Gaddipati GN, Müller NLF, et al. Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.04.006

BibTeX
@article{Peruzzo2025,
  author = {Peruzzo, Nicolas and Lenz, Gabriel and Akhiwu, Ted and Bilalaga, Mariah and Gaddipati, Greeshma Nihitha and Müller, Nathalia Luisy Farias and Zarpellon, Loren and Venero, Fernando and Corassa, Marcelo and Cardona, Andrés F and Reuss, Joshua E and Pellini, Bruna},
  title = {Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.04.006}
}
Kostenlos starten →